Cello Health PLC – Preliminary Results
Cello Health plc (AIM:CLL), the healthcare-focused advisory group, today announces its results for the year to 31 December 2018.
Financial Highlights
|
|
2018 |
2017 |
% |
|
|
|
|
|
|
Reported basic earnings per share |
6.27p |
4.09p |
↑53.3% |
|
Headline basic earnings1 per share |
9.02p |
7.93p |
↑13.7% |
|
Net funds |
£6.3m |
£1.6m |
|
|
Full year dividend |
3.85p |
3.50p |
↑10.0% |
|
Net revenue |
£104.8m |
£102.5m |
↑2.3% |
|
Group headline profit before tax |
£12.2m |
£11.4m |
↑6.4% |
|
Reported profit before tax |
£8.4m |
£5.8m |
↑44.7% |
[1] Headline basic earnings per share is defined in note 8
Operational Highlights
- Continued progress towards strategic goals
- Renaming of Group to Cello Health plc
- 2017 acquisitions continue to perform well
- Cello Health continues to broaden and deepen the client offer
- Top 20 clients represented 40.1% of net revenue (2017: 38.9%)
- Well positioned for further international expansion, with Philadelphia and Berlin office opened
- Sunday Times “100 Best Companies to Work For 2019”
- Good progress with the Signal Health offer
- Pulsar developing strong client links with Cello Health
Board Development
- Chris Jones appointed as Non-Executive Chairman
- Julia Ralston, CEO Cello Health US, appointed to the plc Board
- Clifford Tompsett appointed as Senior Independent Non-Executive Director
- Jo LeCouilliard and Michele Luzi appointed as independent Non-Executive Directors
Mark Scott, Chief Executive, commented:
“2018 marked an important moment in Cello’s development as we changed our name to Cello Health plc to reflect our ongoing strategic focus and developed our Board to support that strategy. It is pleasing to see strong earnings per share growth and we have accordingly increased our dividend for the thirteenth successive year. We now intend to build on this momentum to support Cello Health’s position as a leading healthcare focused advisory group globally.”